Biotech Values

[mgm3]

OK, I agree with you. Mentioning preclinical studies without also mentioning the outstanding clinical data from the phase-1/2 AMD trial is pretty odd.

This could very well be explained by unsophisticated performance from the PR firm that seems to be handling press releases. I think the explanation is probably something as simple as an oversight rather than something nefarious. GENR does show a "ditz" factor occasionally.